Cancer biomarkers: knowing the present and predicting the future.
Cancer biomarkers: knowing the present and predicting the future.
复制标题
DOI：
10.1517/14796694.1.1.37
复制
发表时间：
2005-02-01
期刊：
影响因子：
--
通讯作者：
Zetter, Bruce R
中科院分区：
文献类型：
--
作者：
Chatterjee, Sabarni K;Zetter, Bruce R
近年来，发现癌症生物标志物已成为癌症研究的一个主要焦点。前列腺特异性抗原在前列腺癌筛查中的广泛使用促使研究人员确定用于筛查不同类型癌症的合适标记物。生物标志物还可用于诊断、监测疾病进展、预测疾病复发和治疗性治疗功效。随着新的和改进的基因组和蛋白质组学技术的出现，如DNA和组织微阵列，二维凝胶电泳，质谱和蛋白质测定与先进的生物信息学工具相结合，有可能开发出能够可靠和准确地预测癌症管理和治疗结果的生物标志物。在未来的几年里，针对癌症每个阶段的血清或尿液检测可能会推动临床决策，补充或取代目前现有的侵入性技术。
In recent years the discovery of cancer biomarkers has become a major focus of cancer research. The widespread use of prostate-specific antigen in prostate cancer screening has motivated researchers to identify suitable markers for screening different types of cancer. Biomarkers are also useful for diagnosis, monitoring disease progression, predicting disease recurrence and therapeutic treatment efficacy. With the advent of new and improved genomic and proteomic technologies such as DNA and tissue microarray, two-dimensional gel eletrophoresis, mass spectrometry and protein assays coupled with advanced bioinformatic tools, it is possible to develop biomarkers that are able to reliably and accurately predict outcomes during cancer management and treatment. In years to come, a serum or urine test for every phase of cancer may drive clinical decision making, supplementing or replacing currently existing invasive techniques.